Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
PZ-128
DRUG
2 trials
Sponsors
Tufts Medical Center
Conditions
Acute Coronary Syndrome
Arterial Occlusive Diseases
Arteriosclerosis
Coronary Artery Disease
Coronary Artery Disease Risk Factors Multiple
Coronary Disease
Heart Diseases
Myocardial Ischemia
+2 more
Phase 1
Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors
Completed
NCT01806077
Tufts Medical Center
Coronary Artery Disease Risk Factors Multiple, Vascular Disease
Start: 2013-04-30
End: 2014-11-30
Updated: 2016-04-21
Phase 2
Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
Completed
NCT02561000
Tufts Medical Center
Acute Coronary Syndrome, Arterial Occlusive Diseases, Arteriosclerosis +5
Start: 2016-05-27
End: 2019-09-17
Updated: 2025-04-16
Related Papers
Deficiency of MMP1a (Matrix Metalloprotease 1a) Collagenase Suppresses Development of Atherosclerosis in Mice
Arteriosclerosis Thrombosis and Vascular Biology
2021-03-25
15 citations
PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization
Arteriosclerosis Thrombosis and Vascular Biology
2020-10-08
35 citations
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease
Arteriosclerosis Thrombosis and Vascular Biology
2015-12-23
103 citations